Fernand Labrie

Publications

Page 5 of 9, showing 50 records out of 429 total, starting on record 201, ending on 250

Publication Category Year
107. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. Intracrinology 1996
363. Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Labrie, F. (1996) Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J. Endocrinol., 150 Suppl.: S43-S50. Intracrinology 1996
450. Blais, Y., Gingras, S., Haagensen, D.E., Labrie, F., Simard, J. (1996). Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol. Cell. Endocrinol., 121: 11-18. Intracrinology 1996
454. Poirier, D., Mérand, Y., Labrie, C., Labrie, F. (1996) D-Ring alkylamide derivatives of estradiol: Effect on ER-binding affinity and antiestrogenic activity. Bioorg. Med. Chem. Lett., 6: 2537-2542. Intracrinology 1996
631. Tchernof, A., Labrie, F., Bélanger, A., Després, J.P. (1996) Obesity and metabolic complications: contribution of DHEA and other steroid hormones. J. Endocrinol, 150: S155-S164. Intracrinology 1996
874. Chen, C., Bélanger, A., Labrie, F. (1996) Adrenal steroid precursors exert potent androgenic action in the hamster sebaceous glands of flank organs and ears. Endocrinology, 137: 1752-1757. Intracrinology 1996
879. Dufort, I., Tremblay, Y., Bélanger, A., Labrie, F., Luu-The, V. (1996) Isolation and characterization of a stereospecific 3beta-hydroxysteroid sulfotransferase (pregnenolone sulfotransferase) cDNA. DNA Cell Biol., 15: 481-487. Intracrinology 1996
884. Labrie, F., Simard, J., Luu-The, V., Bélanger, A., Pelletier, G., Morel, Y., Mebarki, F., Sanchez, R., Durocher, F., Turgeon, C., Labrie, Y., Rhéaume, E., Labrie, C., Lachance, Y. (1996) The 3beta-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3beta-HSD congenital deficiency, in: Proceeding 9th European Testis Workshop Signal Transduction in Testicular Cells - Basic and Clinical Aspects, Springer-Verlag, pp 185-218. Intracrinology 1996
886. Li, X., Singh, S.M., Luu-The, V., Côté, J., Laplante, S., Labrie, F. (1996) Vinyl fluoride as a mimic of the "intermediate" enol form in the 5alpha-reductase transformation: synthesis and in vitro activity of (N-1',1'-dimethylethyl)-3-haloandrost-3,5-diene-17beta-carboxamides. Bioorg. Med. Chem., 4: 55-60. Intracrinology 1996
887. Lin, S.-X., Zhu, D.-W., Azzi, A., Campbell, R.L., Breton, R., Labrie, F., Ghosh, D., Pletnev, V., Duax, W.L., Pangborn, W. (1996) Studies on the 3D-structure of estrogenic 17beta-hydroxysteroid dehydrogenase. J. Endocrinol., 150 Suppl.: S13-S20. Intracrinology 1996
888. Lopez-Solache, I., Luu-The, V., Séralini, G.E., Labrie, F. (1996) Heterogeneity of rat type I 5alpha-reductase cDNA: cloning, expression and regulation by pituitary implants and dihydrotestosterone. Biochim. Biophys. Acta, 1305: 139-144. Intracrinology 1996
889. Luu-The, V., Bernier, F., Dufort, I., Labrie, F. (1996) Molecular biology of steroid sulfotransferase. Ann. N.Y. Acad. Sci., 784: 137-148. Intracrinology 1996
890. Morissette, J., Durocher, F., Leblanc, J.-F., Normand, T., Labrie, F., Simard, J. (1996) Genetic linkage mapping of the human steroid 5alpha-reductase type 2 gene (SRD5alpha2) close to D2S352 on chromosome region 2p22-23. Cytogenet. Cell. Genet., 73: 304-307. Intracrinology 1996
892. Simard, J., Durocher, F., Mébarki, F., Turgeon, C., Sanchez, R., Labrie, Y., Couet, J., Trudel, C., Rhéaume, E., Morel, Y., Luu-The, V., Labrie, F. (1996) Molecular biology and genetics of the 3beta-hydroxysteroid dehydrogenase/delta5/delta4 isomerase gene family. J. Endocrinol., 150 Suppl.: S189-S207. Intracrinology 1996
893. Simard, J., Rhéaume, E., Sanchez, R., Mebarki, F., Morel, Y., Zerah, M., New, M.I., Labrie, F. (1996) Relation between molecular defect and phenotypic manifestation of human 3beta-hyroxysteroid dehydrogenase deficiency, in: New, M., ed. Frontiers Endocrinol., Serono Symposia Series, pp 39-68. Intracrinology 1996
83. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. Intracrinology 1997
85. Labrie, F., Simard, J., Candas, B. (1997) Reply by the authors to: Editorial comment of: Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters [Reply to the authors/P.F. Schellhammer]. Urology, 49: 586-589. Intracrinology 1997
88. Luo, S., Chen, C., Labrie, C., Candas, B., Singh, S.M., Labrie, F. (1997) Daily dosing with Flutamide or Casodex exerts maximal antiandrogenic activity. Urology, 50: 913-919. Intracrinology 1997
89. Simard, J., Labrie, F. (1997) Recent advances in androgen receptor research: relative potencies of pure antiandrogens and implications for prostate cancer therapy, in: New diagnostic and treatment modalities in prostate cancer, Project in Knowledge, pp 15-23. Intracrinology 1997
90. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. Intracrinology 1997
438. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. Intracrinology 1997
439. Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Effect of dehydroepiandrosterone (DHEA) on bone mass, serum lipids, and dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 3387-3394. Intracrinology 1997
440. Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Long-term inhibitory effects of a novel anti-estrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int. J. Cancer, 73: 735-739. Intracrinology 1997
441. Luo, S., Martel, C., Sourla, A., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int. J. Cancer, 73: 381-391. Intracrinology 1997
442. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. Intracrinology 1997
443. Luo, S., Stojanovic, M., Labrie, C., Labrie, F. (1997) Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int. J. Cancer, 73: 580-586. Intracrinology 1997
444. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S.M., Mérand, Y., Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112. Intracrinology 1997
445. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497. Intracrinology 1997
447. Sourla, A., Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Morphological changes induced by six-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology, 138: 5605-5617. Intracrinology 1997
448. Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguère, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol., 11: 353-365. Intracrinology 1997
622. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997) Physiological changes in DHEA are not reflected by the serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab., 82: 2403-2409. Intracrinology 1997
623. Labrie, F., Bélanger, A., Cusan, L., Gomez, J.L., Candas, B. (1997) Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 82: 2396-2402. Intracrinology 1997
624. Labrie, F., Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Candas, B. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab., 82: 3498-3505. Intracrinology 1997
855. Labrie, F., Luu-The, V., Lin, S.-X., Labrie, C., Simard, J., Breton, R., Bélanger, A. (1997) The key role of 17beta-HSDs in sex steroid biology. Steroids, 62: 148-158. Intracrinology 1997
857. Lourdusamy, M., Coté, J., Laplante, S., Labrie, F., Singh, S.M. (1997) Synthesis and in vitro Study of 17beta-(N-Ureylne-N, N'-disubstituted)-4-methyl-4Aza-5alpha-androstan-3-ones as Selective Inhibitors of Type I 5alpha-Reductase. Bioorg. Med. Chem., 5: 305-310. Intracrinology 1997
864. Luu-The, V., Simard, J., Labrie, C., Bélanger, A., Labrie, F. (1997) Intracrinology and hormone-dependent cancers. Rev. Clin. Pharmacol., 11: 18-26. Intracrinology 1997
865. Poulin, M.-J., Simard, J., Catford, J.-G., Labrie, F., Piché, Y. (1997) Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens. Mol. Plant. Microbe Interactions, 10: 481-487. Intracrinology 1997
73. Chen, C., Li, X., Singh, S.M., Labrie, F. (1998) Activity of 17beta-(N-alkyl/arylformamido)- and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol., 111: 273-278. Intracrinology 1998
75. Labrie, F. (1998) Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer, 5: 341-351. Intracrinology 1998
76. Labrie, F. (1998) Optimizing combined androgen blockade in prostate cancer, in: Belldegrun, A., Kirby, R.S. et Oliver, R.T.D., eds: New Perspectives in Prostate Cancer, England, ISIS Medical Media, pp 293-311. Intracrinology 1998
77. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. Intracrinology 1998
78. Pelletier, G., Luu-The, V., Huang, X.F., Lapointe, H., Labrie, F. (1998) Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol., 160: 577-582. Intracrinology 1998
80. van der Kwast, T., Têtu, B., Suburu, E.R., Gomez, J., Lemay, M., Labrie, F. (1998) Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol., 186: 406-409. Intracrinology 1998
425. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. Intracrinology 1998
426. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. Intracrinology 1998
428. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. Intracrinology 1998
429. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. Intracrinology 1998
430. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. Intracrinology 1998
431. Martel, C., Provencher, L., Li, X., St-Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., Labrie, F. (1998) Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205. Intracrinology 1998
432. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. Intracrinology 1998
<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards